Abstract 621P
Background
Early detection of primary liver cancer (PLC) in patients with liver cirrhosis (LC) or chronic hepatitis virus infection (CHVI) improves survival. The urgent need is convenient and affordable tools with high sensitivity to facilitate timely diagnosis.
Methods
Tissue and plasma samples from 159 healthy individuals and 89 PLC, LC, or CHVI patients were sequenced by a targeted methylation panel (∼70,000 CpGs) to identify candidate methylated DNA markers (MDMs). In phase I, the performance of each selected MDMs was validated in 175 plasma samples (PLC, n=101; LC/CHVI, n=74) by CO-methylation aMplification rEal-Time PCR (COMET) assay. A logistic model was then trained and validated in phase II with 310 plasma samples (hepatocellular carcinoma [HCC], n=212; combined hepatocellular-cholangiocarcinoma [cHCC-CC], n=12; CHVI, n=106; training vs. validation, 2:1).
Results
The 11 selected MDMs with top performance consistently showed significant differences in tissue samples between PLC and LC/CHVI, as well as in plasma samples between PLC and LC/CHVI (P<0.05). In phase I, 8 of the above 11 MDMs with an area under the curve (AUC) over 0.80 to differentiate PLC and LC/CHVI were selected for further investigation. In phase II, the MDM-based model achieved sensitivity of 87.2% (95% confidence interval [CI], 80.8%–92.4%) and 88.0% (78.4%–94.4%), at respective specificity of 97.1% (90.1%–99.7%) and 100% (90.3%–100%) in the training and validation sets. In the validation set, sensitivity in patients with BCLC stage 0, diameter<3 cm, AFP-negative and PIVKA-II-negative was 90.0% (55.5%–99.7%), 88.9% (65.3%–98.6%), 80.6% (64.0%–91.8%), and 81.3% (54.4%–96.0%), respectively. Additionally, our model detected 19 of 24 (79.3%, 57.8%–92.9%) intrahepatic cholangiocarcinoma. Combining AFP and PIVKA-II, the model achieved higher sensitivity of 93.3% (85.1%–97.8%) and specificity of 100.0% (90.3%–100%).
Conclusions
COMET featuring low cost and high accuracy exhibits preferable potential for PLC detection in patients with LC or CHVI. Further validation in a prospective cohort is warranted.
Clinical trial identification
NCT05996666, release date 08/10/2023.
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China (No: 81972726 and 82273074), Dawn Project Foundation of Shanghai (No: 21SG36), Shanghai Health Academic Leader Program (No. 2022XD001).
Disclosure
X. Zhu, L. Zhang, Q. You, J. Xu, Y. Xu, H. Lu, B. Li, G. Wang, S. Cai: Financial Interests, Personal, Full or part-time Employment: Burning Rock Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract